Trials / Completed
CompletedNCT02721537
Use of 31P MRS to Assess Brain NAD+ in Healthy Current and Former Collegiate Athletes
Use of 31P MRS to Assess Brain NAD+ in Healthy Current and Former Collegiate Athletes and a Comparison of the Effect of Nicotinamide Riboside Supplementation on Brain NAD+ Levels
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Mayo Clinic · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
Can nicotinamide riboside (750 mg/day for 12 weeks) affect the levels of NAD+ in the brain as measured by 31P MRS?
Detailed description
Healthy collegiate athletes (football, soccer, rugby, hockey, and volleyball) will take Nicotinamide Riboside (NR) or placebo twice daily for 84 days. Pre- and post-intervention evaluations include physical assessment, blood tests for safety and toxicity monitoring, blood tests for biomarkers, neurologic testing, quality of life questionnaires, and the 31P MRI exam.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | Nicotinamide Riboside | Three capsules, twice per day for 84 days |
| OTHER | Matching placebo | Three matching capsules, twice per day for 84 days |
Timeline
- Start date
- 2016-09-01
- Primary completion
- 2022-08-01
- Completion
- 2022-08-01
- First posted
- 2016-03-29
- Last updated
- 2022-08-03
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02721537. Inclusion in this directory is not an endorsement.